Abstract
Inflammatory breast cancer (IBC) is rare but is the most aggressive type of breast cancer. Patients with IBC have characteristic clinical presentations resembling inflammatory process, including rapid onset and progression of breast swelling, redness, edema, tenderness, and warmth because of diffuse dermal lymphatic occlusion by tumor emboli. 1 IBC is often associated with early metastasis and resistance to conventional therapies and poor clinical outcomes. Despite multidisciplinary approaches and multimodality treatment comprising neoadjuvant chemotherapy, radical surgery, adjuvant radiotherapy, and, if the patient is eligible, antihormonal and anti-human epidermal growth factor receptor 2 (HER2) therapy, the clinical outcomes of patients with IBC remain poor, with a 5-year overall survival (OS) rate of around 40%. 1, 2 Thus, it is imperative to identify innovative biomarkers related to the biologic behavior of IBC and to predict the effectiveness of novel therapeutic agents for these patients.
Programmed cell death 1 (PD-1) and its ligand, programmed death ligand 1 (PD-L1), play important roles in tumor surveillance. The interaction of PD-1 and PD-L1 leads to downregulation of the T-cell-mediated immune response to tumor cells. [3] [4] [5] [6] PD-L1 is a cell surface glycoprotein and is expressed by immune cells (such as T and B cells, macrophages, and dendritic cells), endothelial cells, and various types of cancer cells. Studies have shown that therapeutic blockade of the PD-1/PD-L1 immune checkpoint reactivates inhibited T cells, which increases antitumor immunity and promotes tumor regression. Objective, durable tumor regression with improved survival due to the blockade has been reported in patients with various advanced cancers, including melanoma, non-small cell lung cancer (NSCLC), kidney cancer, and bladder cancer. [7] [8] [9] [10] Furthermore, findings that positive PD-L1 expression predicts a higher likelihood of objective response to anti-PD-L1 agents have been reported in most studies. 9, [11] [12] [13] Studies of PD-L1 expression in breast cancer are relatively scant in the literature. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] The reported PD-L1 expression rate in breast cancer has varied substantially (1.7%-80%), likely owing to differences in testing methods, antibody clones, and scoring strategy. 26, 30, 31 Furthermore, different studies have been contradictory regarding the prognostic effect of PD-L1 expression. Quite a few such studies have been focused on triple-negative breast cancer (TNBC) because of the aggressive natural history and the lack of targeted therapy of TNBC. [20] [21] [22] [23] [24] 26, 28 Compared with other breast cancer subtypes, TNBC and basal-like breast cancer have higher PD-L1 expression rates. [15] [16] [17] 25, [32] [33] [34] Small-scale clinical trials targeting the PD-1/PD-L1 axis in patients with recurrent/metastatic TNBC have shown encouraging results, with durable objective responses and an acceptable safety profile. [35] [36] [37] In a phase Ib clinical trial in patients with advanced TNBC, Nanda et al 35 reported that using an anti-PD-L1 monoclonal antibody (pembrolizumab) resulted in an overall response rate of 18.5% in heavily pretreated, advanced, PD-L1-positive TNBC. Similar findings were reported by two other studies using another type of anti-PD-L1 agent (MPDL3280A, also called atezolizumab). 36, 38 These promising results in initial clinical trials have inspired the evaluation of PD-L1 expression in IBC. So far, only two studies have investigated PD-L1 expression in IBC. 39, 40 Bertucci et al 39 used DNA microarrays to evaluate PD-L1 messenger RNA (mRNA) expression in 112 pretherapeutic IBC samples and 194 non-IBC samples, and they reported that PD-L1 mRNA was upregulated in 38% of the IBCs and in 28% of the nonIBCs. Hamm et al 40 used immunohistochemical (IHC) staining to stain 12 IBC tumors and reported low-intensity PD-L1 staining in three tumors and high-intensity PD-L1 staining in one tumor; also, a subset of the IBC tumors was associated with high CD8+/PD-L1+ lymphocyte infiltration.
In the present study, we retrospectively evaluated the prevalence of PD-L1 protein expression in a cohort of IBC tumors with a long follow-up duration. The PD-L1 expression was detected using IHC staining, which has been routinely used for patients with NSCLC and melanoma. We also assessed the association of PD-L1 expression of the IBCs with clinicopathologic parameters and long-term clinical outcomes.
Materials and Methods

Patients
This study included patients with primary IBC who were treated at The University of Texas MD Anderson Cancer Center from September 1994 through August 2004 with available tumor tissue for analysis and clinical follow-up information. Diagnosis; preoperative and postoperative treatments; biomarker studies encompassing estrogen receptor (ER), progesterone receptor (PR), and HER2 status; and tissue microarray (TMA) construction have been previously reported by our group for these patients. 41 Three cores (each 1.0 mm in dimension) for each tumor were used for this study. TMA was built up using post-neoadjuvant resected residual tumors because many pretreated core needle biopsy samples (mostly obtained at local hospitals) were not available. Patients with pathologic complete response were not included. A total of 68 patients and their tumor tissue were analyzed in this study. This study was approved by the institutional review board.
PD-L1 Expression
Immunohistochemical staining for PD-L1 was performed on 4-µm-thick paraffin sections of TMA slides. Each tumor had three cores obtained from different areas of the tumor. Antigen retrieval was conducted by steaming the slides in 10 mmol/L citrate buffer (pH 6.0) for 25 minutes. The sections were incubated with the primary monoclonal rabbit anti-PD-L1 antibody, clone 28-8 (pharmDX; Dako, Carpinteria, CA) with Autostainer Link 48 (Dako), followed by the EnVision FLEX visualization system (Dako) per the manufacturer's instructions. The combination of this PD-L1 clone and detection system was approved by US Food and Drug Administration (FDA) for selecting patients with NSCLC and melanoma for anti-PD-L1 therapy (ie, nivolumab). 42 The tissues were then counterstained with Mayer's hematoxylin solution and evaluated under a light-field microscope.
The staining results were evaluated with known positive and negative tissue controls. Percentage of membranous staining in viable invasive tumor cells was enumerated and recorded for each case. Interpretation of IHC staining was performed independently by three pathologists (J.H., J.Z., and Y.G.). Discrepancies among the three pathologists were resolved by discussion at a multihead microscope until a consensus was reached. Positive PD-L1 expression was defined as when more than 1% of viable invasive tumor cells showed partial or complete membranous staining at any intensity, according to previous studies. 9, 12, 34 Staining intensity for positive cases was scored as weak, moderate, or strong. The correlations © American Society for Clinical Pathology AJCP / Original article of PD-L1 expression with clinicopathologic parameters and survival data were evaluated.
Statistical Analyses
Fisher exact test was used to evaluate associations between PD-L1 expression and clinicopathologic variables. OS was calculated from the date of initial pathologic diagnosis of the primary tumor to the date of death from any cause or the last follow-up date. Of note, OS and disease-specific survival were highly correlated (data not shown); therefore, only OS data are presented. OS was estimated by the Kaplan-Meier method, and distributions were compared using the log-rank test. Cox proportional hazards regression was used to assess the association between OS and PD-L1 expression and clinicopathologic factors.
Univariate Cox proportional hazards and Firth penalized (for covariates with zero deaths) regression models were used to test the associations between several potential prognostic factors and OS. From these models, hazard ratios (HRs) for each potential prognostic factor and corresponding 95% confidence intervals (CIs) were estimated. All potential prognostic factors with P values of less than .10 in the univariate analysis were then included in multivariate Cox models. All analyses were two-sided, and P values of .05 or less were considered statistically significant. Statistical analyses were carried out using R version 3.3.1 (R Foundation for Statistical Computing, Vienna, Austria).
Results
The clinicopathologic characteristics of the patients studied are summarized in ❚Table 1❚. Of the 68 patients with IBC included in this study, 52 (76.5%) were white, 12 (17.6%) were Hispanic, and four (5.9%) were of other races/ethnicities. Patient age at the time of the initial diagnosis ranged from 23 to 75 years (median, 48 years). Fifty-two patients had stage IIIb disease, 10 had stage IIIc disease, and six had stage IV disease. Sixty patients received chemotherapy, and 21 patients received hormonal treatment.
Lymph One patient had the same date recorded for diagnosis and last follow-up and hence was excluded from survival analysis. Of the remaining 67 patients, the median follow-up time was 3.75 years (range, 0.29-17.54 years). The median OS time was 3.78 years (95% CI, 2.45-10.17 years). The 5-year OS rate was 43.4% and the 10-year OS rate was 36.4%. Forty-four deaths had occurred among these patients by the time of analysis.
Correlation of PD-L1 Expression With Clinicopathologic Parameters and Outcomes
Positive PD-L1 expression in tumor cells was found in 25 (Table 1) . In univariate analysis, worse OS was significantly associated with positive PD-L1 expression (P = .040), negative ER status (P = .008), and triple-negative status (P = .048) ❚Table 2❚. The 5-year OS rate was 36.4% for patients with PD-L1-positive tumors and 47.3% for those with PD-L1-negative tumors ❚Figure 1❚. In multivariate analyses, PD-L1 status remained a statistically independent predictor of OS in a Cox model including race/ethnicity and ER status (HR, 1.90; 95% CI, 1.03-3.50; P = .042); similar yet slightly attenuated results were observed in a separate Cox model including race/ethnicity and triple-negative status (HR, 1.76; 95% CI, 0.95-3.25; P = .078). Of note, because of their strong association, ER and triple-negative status could not both be included in a significant multivariate model.
Discussion
Recent clinical trials have demonstrated that anti-PD-L1 therapy leads to an objective, substantive, and durable response in patients with various advanced malignancies, and positive PD-L1 expression predicts better response to this therapy in most studies. At the moment, IHC staining for PD-L1 is the best predictive biomarker to identify patients who are most likely to respond to anti-PD-L1 therapy. For patients with IBC, obtaining information of PD-L1 expression in their tumors and its clinicopathologic implication is the first step before considering potential application of anti-PD-L1 therapy. In this study, we determined PD-L1 expression in a cohort of IBC tumors using an antibody clone and IHC detection system that has been approved by the FDA for NSCLC.
Our study showed that PD-L1 was expressed in 36.8% of IBC tumors and that worse OS was significantly associated with positive PD-L1 expression, negative ER status, and triple-negative status. We also demonstrated that positive PD-L1 expression was associated with unfavorable OS in univariate and multivariate analyses. However, we did not find statistically significant associations between PD-L1 expression and any of the clinicopathologic variables examined. The PD-L1 expression rate in our study is similar to what has been reported by two IBC study groups. Bertucci et al 39 used DNA microarray to evaluate PD-L1 mRNA and observed PD-L1 overexpression in 38% of IBC samples and 28% of non-IBC samples. In addition, PD-L1 mRNA overexpression in IBC was reportedly associated with ER-negative status, basal and HER2-enriched aggressive subtypes, and better pathologic response to chemotherapy but was not associated with metastasis-free survival and overall specific survivals. Hamm et al 40 reported that four (33.3%) of 12 IBC tumors expressed PD-L1 and, as in our findings, most positive cases had low staining intensity by IHC. The evaluation of PD-L1 expression is challenging owing to the lack of a standardized and reproducible staining method and interpretation protocol. To date, most studies addressing PD-L1 expression in breast cancer have used IHC staining on formalin-fixed, paraffin-embedded tissue with variability in antibody clones, scoring methods, and cutoffs to define positive expression and reported prevalence varying considerably, from 1.7% to 80% ❚Table 3❚. [14] [15] [16] [18] [19] [20] [21] [23] [24] [25] [26] [27] [28] The lack of consensus standards in PD-L1 detection makes the reliability of these study results a bit skeptical.
In addition to the inconsistent expression rate of PD-L1 by IHC found in breast cancer, the prognostic value of PD-L1 as to whether PD-L1 expression is a favorable or adverse prognostic variable in breast cancer has been contradictory in the literature. In fact, similar conflicting results are seen not only in breast cancer research but also in studies of other cancer types. Given the immunosuppressive role of PD-L1 in mediating an immune evasion mechanism, PD-L1 expression may plausibly be associated with a poor prognosis. PD-L1 has been shown to be an unfavorable predictor in NSCLC, 44, 45 melanoma, [46] [47] [48] renal cell carcinoma, 49-51 hepatocellular carcinoma, 52 pancreatic carcinoma, 53 esophageal carcinoma, 54 gastric carcinoma, 55 colorectal carcinoma, 56 and ovarian carcinoma. 57 A meta-analysis of 3,107 patients with various solid tumors reported a similar association. 58 However, the opposite findings are not uncommon, and the association of PD-L1 expressions in tumor cells with better outcomes has been reported in NSCLC, 59 melanoma, 12 Merkel cell carcinoma, 60 and colorectal cancer. 61 In breast cancer, the frequency of PD-L1 expression (as measured by IHC) in tumor cells and the association of this expression with clinicopathologic variables and prognostic effect in 13 key studies are summarized in Table 3 . Consistent with our findings, several studies showed an adverse prognostic effect of PD-L1 expression (Table 3) . 14, 16, 25, 32 Muenst et al 14 found that PD-L1 expression was significantly associated with high tumor grade and Ki-67 index, large tumor size, positive nodal status, and negative ER status, and positive PD-L1 was an independent negative prognostic factor for OS. Similar findings were reported in two other studies by Li et al 25 and Qin et al. 16 Soliman et al 32 also examined 61 breast cancer specimens using IHC and found an association between PD-L1 protein expression and positive lymph node status. These findings suggest that PD-L1 expression in tumor cells may facilitate activation of the PD-1/PD-L1 pathway and allow the tumor cells to evade antitumor immune surveillance and consequently 
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AJCP / Original article proliferate and spread more rapidly. Notably, most of these studies reported a significant association between positive PD-L1 expression in tumor cells and unfavorable clinicopathologic features (Table 3) , [14] [15] [16] 18, 19, 21, 23, 25, 27 suggesting that PD-L1 may be a high-risk factor in patients with breast cancer. Interestingly, despite its association with poor clinicopathologic features, including distant recurrence in one study, 19 PD-L1 expression in tumor cells was paradoxically associated with improved survival in some of these studies (Table 3) . 15, 18, 19, 21 The biologic mechanism of such dilemma is not yet understood.
Beckers et al 20 examined PD-L1 expression in 161 TNBC samples and reported that cytoplasmic PD-L1 staining, but not membranous staining, was significantly associated with a lower risk of cancer-specific death. Li et al 24 reported a significant association between disease-free survival and positive PD-L1 expression in stromal cells but not in tumor cells. A recent study reported that PD-L1 expression by tumor cells was not associated with recurrence-free survival or OS; however, the combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes was associated with a poor prognosis in 248 TNBC samples. 43 The variation in the prevalence and clinical implications of PD-L1 expression could be attributed, at least in part, to differences in cohort size, sample type (eg, tissue microarray vs whole section or frozen tissue vs formalin-fixed, paraffin-embedded tissue), IHC methods, antibody clones, scoring methods (eg, H-score vs percentage of positive cells), cutoff values, and composition of cancer subtypes in the study population (eg, basal or triple-negative type vs all types). 26, 30, 31 Because of the concerns regarding the reliability of IHC staining for PD-L1, two previous studies used mRNA-based tests. 17, 29 Schalper et al, 29 using in situ mRNA hybridization, reported PD-L1 mRNA expression in 60% of 636 breast tumors in TMAs, and positive expression was significantly associated with longer recurrence-free survival. Sabatier et al 17 reported that PD-L1 gene expression based on gene microarrays was upregulated in 20% of all clinical samples and 38% of basal cancers. The high expression was associated with larger tumor size, higher grade, negative ER and PR status, positive HER2 and Ki-67 status, and basal and HER2-enriched subtypes. However, upon survival analysis, PD-L1 upregulation was not associated with survival in the whole population but was associated with better metastasis-free and overall specific survivals in basal cancers.
Owing to its technical feasibility, IHC remains the most commonly used method to detect PD-L1 expression. In this study with IBC samples, we adopted the FDA-approved IHC technique, antibody clone, and scoring strategy that are currently used for NSCLC and melanoma with the hope that the result would be more reliable. Our study is important because, to our knowledge, it is the first large study of PD-L1 expression in IBC (as measured by IHC) with a long duration of clinical follow-up information. This study demonstrated PD-L1 expression in more than one-third of IBCs examined, indicating that these tumors are potential candidates for innovative PD-L1-targeting agents, especially for patients whose tumor progressed on conventional therapies. With the encouraging results for anti-PD-L1 monoclonal antibodies in the ongoing clinical trials of breast cancer, 35, 36, 38, 62 it is reasonable to believe that PD-L1 inhibitors could be implemented in patients with IBC in the future.
Our study has several limitations. First, all the patients with IBC required neoadjuvant chemotherapy, and a subset of pretreated core needle biopsy samples that were obtained at local hospitals was unavailable for the PD-L1 study. Thus, post-neoadjuvant resected tumors that were obtained at our institution were used. Second, because of rarity of IBC tumors, the study series comprised a modest sample size of patients with IBC, although this cohort remained the largest series compared with those reported in the literature. Third, PD-L1 IHC expression was assessed on TMA, as in many other such studies (Table 2) , [14] [15] [16] [18] [19] [20] 23, 28 and small tumor pieces in TMA may lead to false-negative results due to intratumoral heterogeneity of PD-L1 expression. 34, 63 However, given the cutoff of PD-L1 positivity being 1%, we believe that possibility of false-negative results should be quite low. On the other hand, to minimize this potential drawback, we used multiple cores from each tumor. Last, TMA cores contain largely tumor cells with minimal or no stromal component and thus are not suitable for evaluating PD-L1 expression in the tumor microenvironment. The expression of PD-L1 in the tumor microenvironment, especially in tumor-infiltrating lymphocytes, was reportedly associated with clinical outcomes and might be of predictive value to immune checkpoint inhibitors. 14, 20, 23, 24, 26 Using whole-tissue sections would overcome the shortcomings associated with TMA.
In a few studies, clinical responses to PD-L1 blockade therapy were observed in patients with PD-L1-negative tumors, 12, 64 indicating that clinical benefit from inhibition of PD-L1 may extend beyond the PD-L1-positive tumor population. Currently, however, positive PD-L1 expression seems to be the best predictor of response to anti-PD-L1 therapy.
In conclusion, our study provides information of PD-L1 expression in IBC tumors and its prognostic relevance. Further studies, preferably prospective, consisting
He et al / PD-L1 in infLammatory Breast CanCer of larger cohorts with whole-tissue sections, are required to further delineate the biologic significance of PD-L1 in IBC tumor cells and stromal components, as well as their prognostic implication and predictive value in relation to anti-PD-L1 therapies. 
